Susvimo (Page 7 of 7)
PRINCIPAL DISPLAY PANEL — Kit Carton
NDC 50242-078-55
Susvimo™
(ranibizumab injection)
See instructions for use
included with the
Susvimo ocular implantwith insertion tool assembly
100 mg/mL
Vial contains 10 mg/0.1 mL ranibizumab
For use with Susvimo ocular implant
Dispense the enclosed Medication Guide to each patient.
Carton contents:
- One Susvimo single-dose vial
- One Susvimo initial fill needle
Rx only
Genentech
10233586
PRINCIPAL DISPLAY PANEL — 10 mg/0.1 mL Vial Carton
NDC 50242-078-12
Susvimo™
(ranibizumab injection)
100 mg/mL
Vial contains
10 mg/0.1 mL ranibizumab
For use with Susvimo
ocular implant
Dispense the enclosedMedication Guide to each patient.
Rx only
1 Single-dose vial
Genentech
10233583
SUSVIMO ranibizumab injection, solution | |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
|
Labeler — Genentech, Inc. (080129000) |
Registrant — Genentech, Inc. (080129000) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Roche Singapore Technical Operations Pte. Ltd. | 937189173 | ANALYSIS (50242-078), API MANUFACTURE (50242-078) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Genentech, Inc. | 080129000 | ANALYSIS (50242-078) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Genentech, Inc. | 004074162 | ANALYSIS (50242-078) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Genentech, Inc. | 833220176 | PACK (50242-078), LABEL (50242-078), ANALYSIS (50242-078) |
Revised: 11/2022 Genentech, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.